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Abstract
Background: Painless, rapid, controlled, minimally invasive molecular transport across human skin
for drug delivery and analyte acquisition is of widespread interest. Creation of microconduits
through the stratum corneum and epidermis is achieved by stochastic scissioning events localized
to typically 250 µm diameter areas of human skin in vivo.
Methods: Microscissioning is achieved by a limited flux of accelerated gas: 25 µm inert particles
passing through the aperture in a mask held against the stratum corneum. The particles scize (cut)
tissue, which is removed by the gas flow with the sensation of a gentle stream of air against the skin.
The resulting microconduit is fully open and may be between 50 and 200 µm deep.
Results: In vivo adult human tests show that microconduits reduce the electrical impedance
between two ECG electrodes from approximately 4,000 Ω to 500 Ω. Drug delivery has been
demonstrated in vivo by applying lidocaine to a microconduit from a cotton swab. Sharp point
probing demonstrated full anaesthesia around the site within three minutes. Topical application
without the microconduit required approximately 1.5 hours. Approximately 180 µm deep
microconduits in vivo yielded blood sample volumes of several µl, with a faint pricking sensation as
blood enters tissue. Blood glucose measurements were taken with two commercial monitoring
systems. Microconduits are invisible to the unaided eye, developing a slight erythematous macule
that disappears over days.
Conclusion: Microscissioned microconduits may provide a minimally invasive basis for delivery of
any size molecule, and for extraction of interstitial fluid and blood samples. Such microconduits
reduce through-skin electrical impedance, have controllable diameter and depth, are fully open and,
after healing, no foreign bodies were visible using through-skin confocal microscopy. In subjects to
date, microscissioning is painless and rapid.
Background
Convenient, cost effective medical technology is needed
to provide better care at lower cost. Minimally invasive
technologies that meet present and future medical needs
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are extremely desirable. There is, for example, a recog-
nized need for improved diabetes treatment [1,2]. With
this in mind, minimally invasive transdermal drug deliv-
ery and analyte sampling are of long-standing interest.
Molecular transport through the skin is fundamentally
limited by the skin's barrier function [3,4]. This has moti-
vated the investigation of active molecular and ionic
transport through relatively unperturbed skin by diffusion
[5] and electrical current (iontophoresis) [6-8]. Other
approaches alter the barrier function by using high voltage
pulses (electroporation) [9], stress waves [10], or by inter-
ventions creating relatively large openings or defects in
the stratum corneum. The latter include cavitation by
ultrasound [11,12], laser drilled openings [13] and chem-
ically-enhanced electroporation [14]. Microneedles and
other sharp devices have also been proposed [15,16]. Of
the many techniques investigated, only the hypodermic
needle has met the major needs. However, needle intro-
duction is often painful.
An alternative means of avoiding these problems is to cre-
ate one or more small holes (microconduits) through the
stratum corneum and underlying tissues (Figures 1 and
2). Techniques using a combination of momentum trans-
fer and scizing are well known in cosmetic dermatology.
The relatively hard, roughened stratum corneum and epi-
dermis resulting from aging processes can be removed by
moderate velocity, sharp particles impinging obliquely
against the skin surface. The hypodermic needle cuts the
tissue and holds it open. Upon needle removal, the tissues
essentially close the opening. In contrast, microscission
can rapidly and painlessly produce small, open microcon-
duits by means of a gas-entrained stream of inert, sharp
particles on a defined skin area (Figure 3). We report here
on the use of scission through a mask to painlessly pro-
duce microconduits in the skin as well as proof-of-concept
drug introduction into and analyte extraction from the
human body.
Methods
Here we describe the exploratory use of sharp particles,
combined with masking techniques, to define small areas
of the skin to be scized. Preliminary experiments were per-
formed using an unmodified Airbrasive Model K, Series II
(S.S. White Mfg. Co, Trenton, NJ, USA). Microscopic com-
parison of various particulates led to the selection of Alu-
minum Oxide Al-602 (Atlantic Equipment Engineers,
Bergenfield, NJ, USA). These fell in the range of 10 µm to
70 µm, with a high percentage of irregular, sharp particles
(Figure 4). Parameters such as particle size, shape, veloc-
ity, flux, carrier gas pressure and nozzle-mask spacing
were varied to investigate their effects on the removal rate
of the stratum corneum and underlying epidermis and
dermis.
A 75 µm thick Teflon mask with one or four holes with a
specified diameter and center-to-center distance was used
to constrain the area of the skin exposed to the abrasive
particles. The mask was mounted on a holder with provi-
sion to position the gas nozzle directly above the mask
(Figure 5, left and right). The mask with a single 200 µm
diameter opening, a 450 µm diameter nozzle and a nozzle
to mask spacing of 1,500 µm was used. The particles in a
nitrogen stream under a pressure of 552 kPa was directed
toward a site on the inner left wrist, 10 cm back from the
center of the palm (Figure 6) of an adult subject. The
proof-of-concept results presented in this paper are based
on experiments on the research team's principal investiga-
tors. The protocol was approved by the Committee on the
Use of Humans as Experimental Subjects at MIT. If the
mask was held tightly against the skin, the stratum cor-
neum, epidermis and dermis were removed to the capil-
lary level in 20 seconds (Table 1). Blood was clearly
visible in the 200 µm diameter microconduit, suggesting
a depth of 100–150 µm. This result led to parameter opti-
mization in five areas.
1. Scizing depends on an optimum incoming particle flux,
related to the mask opening diameter. Lower and higher
fluxes reduce scizing rates. Excess particles per unit time
tend to clog the mask opening and cause particle trapping
between the mask and stratum corneum. At this limit,
excess particles impede the entry and exit of particles,
slowing the scizing process. The particle generator has a
pressurized particle reservoir, the bottom of which is sep-
arated from the carrier gas path by a thin aperture plate
with holes in it. This system is vibrated by an electrical
solenoid with motion amplitude control to provide con-
trolled delivery of microparticles into the gas stream. This
arrangement was modified by replacing the eight, 500 µm
diameter holes with a single 325 µm diameter opening,
giving a particle flux that produced a peak scission rate
near the maximum shake amplitude.
2. High gas pressure deflected the stratum corneum away
from the mask, causing particle trapping and poor micro-
conduit definition due to loss of particulate collimation.
Experiments on test polyethylene substrates that are 'soft'
and on human skin in vivo showed the scission rate to be
the same at 103 to 172 kPa as at 552 kPa.
3. The particle flux was initially observed to vary signifi-
cantly due to the reservoir shake solenoid, synchronized
with valving in the gas stream creating large pressure
pulses. This variability was greatly decreased by removing
all gas flow controls and externally actuating the reservoir
vibration solenoid. A voltmeter was installed in the shake
solenoid to permit accurate shake amplitude repeatabil-
ity. After the gas pressure is turned on and flow estab-
lished for ten seconds, the shake solenoid is energized.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/12
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This sequence is reversed to turn the system off. A full
cycle particle flux variation of 4% is achieved, with the
flux during scission constant to within 2%.
4. Carbide nozzles (S.S. White Mfg. Co, Trenton, NJ, USA)
with aperture diameters of either 275 µm or 450 µm were
used. Smaller diameters clogged, and larger diameters
produced excessively large flux diameters at the mask sur-
face for the single or four hole masks used throughout. A
nozzle to mask spacing of 750–850 µm produces a 3,800
µm diameter flux cone. This exposes the surface of the
stratum corneum to approximately 350–500 particles per
second through each 150 µm diameter hole in the one or
four opening masks at a shake voltage of 74 V and nitro-
gen gas pressure of 138 kPa. These parameters give a sciz-
ing rate of approximately 10–15 µm per second on the
stratum corneum of adult subjects who participated in the
in vivo trials. The mask holder with the four nozzle array
below it is shown (Figure 5, left). The mask is cut to extend
beyond the circular ring that presses it against the stratum
corneum. The square hole that rigidly fixes the nozzle
location in three axes is above it. The rectangular arm
extending left acts as a bridge over which a strap around
the wrist pulls the holder against the wrist. At the left end
is a square, electrically insulating plate that acts as a stabi-
lizing fulcrum. The four-hole mask (Figure 5, right) is seen
from the stratum corneum side, backed by a thin metal
plate with a hole having a 100 µm ridge around its edge
that presses the mask against the stratum corneum. Three
nozzles are just visible through the mask.
5. Polyimide film – a hard, electrically insulating, high
temperature polymer – was used for scission rate testing
and as a mask material. It exhibited the same resistance to
mask thinning by impinging particles as teflon, which
scize less rapidly than glass or stainless steel. Polyimide
Physical effects of hypodermic needle and microconduit Figure 1
Physical effects of hypodermic needle and microconduit.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/12
Page 4 of 11
(page number not for citation purposes)
can be shaped readily by laser ablation, drilling, chemical
or plasma etching, lending itself to low cost, mass pro-
duced single-use masks. Polyimide mask life time is 60–
90 seconds, equivalent to opening five to eight microcon-
duits 150 µm deep, providing ample margin for a single
scizing operation. Beyond this life time, the masking
holes in polyimide increase in size by extended abrasion.
Results and discussion
Scized microconduits in vivo
Attempts to do in vitro testing were abandoned when
properties of human cadaver skin were found to be quite
different from in vivo skin. There was considerable sam-
ple-to-sample variability in the stratum corneum thickness
and the skin impedance in human cadaver skin prior to
microscissioning. The variability may have been caused by
the preservation techniques, length of time between death
and skin harvest and the site of skin on the body. Superfi-
cial mechanical state of the skin varied from tough to
Size comparison of hypodermic needle to a microconduit Figure 2
Size comparison of hypodermic needle to a microconduit.
Process of masked scission Figure 3
Process of masked scission.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/12
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Al2O3 scizing particulate (marked width upper center = 35 µm) Figure 4
Al2O3 scizing particulate (marked width upper center = 35 µm).
Mask holder and nozzle fixture: Left: Mask/nozzle holder and wrist fixture; Right: Close up of 4-hole mask and nozzles Figure 5
Mask holder and nozzle fixture: Left: Mask/nozzle holder and wrist fixture; Right: Close up of 4-hole mask and nozzles.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/12
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near-disintegration among samples. As the wide range of
possible applications became apparent, a decision was
made to demonstrate proofs-of-concept only. Reliable
demonstration of drug delivery (lidocaine), analyte sam-
pling (blood glucose) and even electrical impedance
measurement were not possible with in vitro testing.
All in vivo results are from experiments done on two adult
subjects. We sterilized the aluminum oxide particulate
and masks by heating to 200°C for one hour. Nozzles,
hoses and the particle reservoir were rinsed in methanol.
Sterile gloves were worn and the target areas swabbed with
ethanol. Sterile saline solution was used for electrical tests
with syringes and needles for handling saline being rinsed
with methanol, and nitrogen dried prior to use.
The depth of scized microconduits can be determined
approximately by measuring the electrical impedance
between an ECG electrode on the subject's unperturbed
skin and the mask holding fixture (Figure 6). A SR715 LCR
meter (Stanford Research, Sunnyvale, CA, USA) operating
at 1 V and 1 kHz was used. The metal mask holder was
electrically connected to the microconduit by normal
saline placed in the ring to which the mask was bonded.
Since the mask was held tight against the skin, the saline
did not leak between the mask and skin, thus providing
electrical continuity with the microconduit. Typical
microconduits generated with a four nozzle, four hole
mask are shown (Figure 7, left and right). The data (Table
1) are averages of approximately 100 experiments on two
subjects. Microconduit depths were measured using the
Vivascope 1000 (Lucid, Rochester, NY, USA), an in vivo
near-infrared reflectance-mode confocal microscope, with
an illumination wavelength of 830 nm, 30 mW power
and a 30 ×, 0.9 N.A. water immersion objective providing
a viewing depth of 200 µm. The instrument captures
images with a spatial resolution of 0.5 to 1.0 µm in the lat-
eral dimension and 3 to 5 µm in the axial dimension. Fur-
ther details of this system have been reported recently
[17]. Standard particle generator parameters were used,
that is, N2 under 138 kPa pressure, reservoir drive of 80 V,
450 µm nozzle diameter.
Microconduit profiles are revealed by infrared confocal
microscopy (Figure 8). Microconduits made with a four
hole mask and a scission time of 20 seconds are shown on
the left. The white lines are an electron microscope grid
placed on the skin to provide high contrast for focusing.
The 160 µm diameter openings are nearly uniform, with
the upper right one corresponding to the upper left image
in the confocal views. The confocal images at nine depths
clearly illustrate that the microconduit is fully open
throughout its depth of approximately 165 µm (lower
right image). At its bottom, the diameter is approximately
65 µm.
Usually there are no residual Al2O3 microparticles, which
are easy to see as bright 30 micrometer particles at full
depth. In some cases, up to about ten microparticles were
observed. However, a deionized water rinse from a hypo-
dermic needle at low pressure is effective in removing par-
ticles. In cases where particles were seen and left, they
were not visible in the confocal microscope at the site after
full healing. This suggests they were moved out by the
healing process, but has not been confirmed by other
methods.
Microscissioning arrangement: Forearm with attaching strap,  mask holder, nozzle, electrical connections to holder and  ECG electrode Figure 6
Microscissioning arrangement: Forearm with attaching strap, 
mask holder, nozzle, electrical connections to holder and 
ECG electrode.
Table 1: Microconduit depth and electrical resistance versus scission time.
Scission time(s) Holder condition Microconduit to ECG resistance Microconduit depth (µm)
No scission Dry 1–3 MΩ 0
No scission Saline 1–3 MΩ 0
2–5 Saline 100–200 kΩ 10–30
10 Saline 50–70 kΩ 30–70
15 Saline 28–35 kΩ 70–100
20 Saline 18–24 kΩ 100–160+BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/12
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Transdermal electrical impedance reduction
Removal of the high electrical resistance stratum corneum
takes place during the initial few seconds of scizing a
microconduit. If stopped, then scizing is a fast, simple,
totally sensation-free method for reducing the electrical
impedance through the skin. At 1 kHz and 1V, the
impedance between two electrocardiogram electrodes
(Type 510–005, Lynn Medical, MI, USA) is approximately
4 kΩ. Placing two of the same type of electrocardiogram
electrodes over two 200 µm diameter shallow microcon-
duits reduces the impedance to 500 Ω, measured under
the same conditions. This implies that the 1 kHz imped-
ance associated with a single microconduit is only 250 Ω,
and, therefore, four microconduits can provide a local
skin resistance of the order of 100 Ω each.
Lidocaine delivery
Assessment of microconduit efficacy for delivering a drug
into the dermis and epidermis was carried out using the
topical anaesthetic, lidocaine. The presence of lidocaine
was evaluated by using non-scarring pulses from a 585
nm pulsed-dye laser, employed as a pain inducer [18].
Also, the 'pin stick' on skin around the microconduit tests
for sensation was used to map lateral anesthesized dis-
tance from the microconduit. Masks with four 160 µm
diameter holes on 450 µm centers were used. Testing was
done on the inner, left wrist, approximately 10 cm away
from the palm center.
The first test determined lidocaine uptake and level of
anesthesia. After scission for 7 seconds, a subject reported
a barely perceptible 'pricking' sensation. The microcon-
duits had an impedance of 23 kΩ, implying a depth of
140 µm. A slight discharge of clear fluid was evident. Both
the microconduit and control sites were exposed to a 50%
lidocaine solution (5 gm lidocaine hydrochloride in 5 ml
normal saline) in saturated filter paper pads with Finn
chambers taped over each. In prior studies, we used 40%
and 50% lidocaine solution and found that the subjective
degree of anesthesia was easily quantifiable by the sub-
jects enrolled in those studies, so we selected 50% lido-
caine concentration for this proof-of-concept
demonstration [18]. These two sites were exposed to a
lidocaine 'soak' for 5 minutes. A third 'normal' control
site, receiving no lidocaine exposure, was marked and
tested. These sites were separated by 5–6 cm. Sensation
testing was done with a Coherent Palomar (Burlington,
MA, USA) Light Sheer Laser emitting a 30 ms, 35 mJ pulse.
The sites were lazed randomly three to five times each,
with and without power on, while the subject's arm was
extended and the subject looked away. The subject ver-
bally reported sensation effects. The testing was carried
out 15, 30 and 75 minutes after lidocaine exposure
(Tables 2 and 3). The sensation data strongly suggest that
the area around microconduits was anesthetized.
A number of additional tests were done using the 'pin
stick' test for sensation, to determine the minimum time
for full anaesthetic effect. Most testing was done on one
subject, with verification tests done on two other subjects.
These tests were done on a single 160 µm diameter
microconduit, 100–150 µm deep on the left inner wrist.
Using 50% lidocaine saturated cotton pads as the anes-
thetic source, anesthesia of a control area without a micro-
In vivo microconduits: Four 150 µm microconduits on 450 µm centers with abrasive particles present in the microconduits  (left) and with particles removed from the microconduits (right) Figure 7
In vivo microconduits: Four 150 µm microconduits on 450 µm centers with abrasive particles present in the microconduits 
(left) and with particles removed from the microconduits (right).BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/12
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Depth profile of a microconduit: Top: Confocal skin surface view of four 160 µm diameter microconduit openings in vivo in  human stratum corneum Figure 8
Depth profile of a microconduit: Top: Confocal skin surface view of four 160 µm diameter microconduit openings in vivo in 
human stratum corneum. Bottom: Cross-section of lower right microconduit (blue arrow) with increasing depth obtained by 
in vivo confocal microscopy.
0 µm 20 µm 40 µm
60 µm 80 µm1 0 0   µm
120 µm1 4 0   µm1 6 0   µmBMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/12
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conduit required 60–90 minutes. Anesthesia became
discernable (sensation diminishes perceptibly) after 1
minute. Maximum anesthetic effect and anesthetized
radius occurred between 2.5 and 3.5 minutes. The anes-
thetized radius was 1,800–2,200 µm. When the lidocaine
was applied to the microconduit under a pressure of 30
inches of water, the full anesthetic effect occurred in 1.5–
2 minutes and the anesthetized radius increased to 2,800–
3,000 µm.
The onset of anesthesia takes longer in microconduits
deep enough to yield blood than in shallower, non-blood
producing microconduits. Possibly the blood outflow
impedes inflow of the externally-applied lidocaine to the
sub-stratum corneum tissues, or the clotting blood par-
tially obstructs the microconduit.
Analyte extraction and analysis
Experiments involving creation of deep microconduits
provided blood samples for glucose testing and
assessment of the sensation (pain) level involved. Testing
was carried out with a FastTake glucose monitor (Lifescan,
Milpitas, CA, USA). The instrument's disposable test strips
required a minimum blood volume of 1.5 µl.
These experiments involved one subject using a subjective
pain sensation scale of one to ten ('none' to 'sharp'). The
test site was always on the side of the left hand fourth
finger or the left hand middle finger between the finger
end and outer joint. The standard mask-nozzle-generator
conditions were used. Opening a microconduit to the
blood capillary level consistently took 14–18 seconds.
Within 3–6 seconds after removing the scizing device, 1–
3 µl of blood formed in a drop (Figure 9, left and right).
The FastTake test strip end was held against the drop and
a sample was drawn into the sensing chamber by capillary
action. Results are summarized (Table 4) comparing
accessing blood with the Penlet II Automatic Blood Sam-
pler (a lancet system supplied with the FastTake instru-
ment) and through microconduits made by scizing. The
tests were done two days apart, with the two lancet tests
first, followed by the scizing tests. Time for the lancet test
is zero due to its rapid plunge in/withdraw action. Times
for scizing were intentionally varied slightly to test sensa-
tion and blood flow effects. The glucose readings were all
in a 'normal' range. These experiments show that scized
microconduits may provide painless acquisition of sam-
ples for established blood glucose tests.
Table 2: Efficacy of lidocaine delivery to tissues through four microconduits.
Site treatment Four microconduits, 
soaked with lidocaine for 5 minutes
Sensation description (at two laser powers)
35 mJ 40 mJ
15 min after lidocaine
Control – no lidocaine, no microconduit Sharp interior pain Sharp interior, very painful
Control – lidocaine, no microconduit Sharp interior pain Sharp interior, very painful
lidocaine microconduit site Hardly perceptible Hardly perceptible
30 min after lidocaine
Repeat 15 minute test sequence No changes in sensation levels
75 min after lidocaine
Control – no lidocaine, no microconduit Sharp interior pain Sharp interior, very painful
Control – lidocaine, no microconduit Sharp interior pain Sharp interior, very painful
lidocaine microconduit site Considerable pain Sharp interior pain
Table 3: Efficacy of lidocaine delivery to tissues through one microconduit.
Site with one microconduit 'Pinprick Test' sensation Anesthetized radius (µm)
Soaked with lidocaine for 1 minute Slight sensation 250
Soaked with lidocaine for 2 minutes No sensation 850
Soaked with lidocaine for 3 minutes No sensation 1,900
Soaked with lidocaine for 4 minutes No sensation 2,200BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/12
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Conclusions
The formation of microconduits in vivo through human
stratum corneum, epidermis and dermis, has been dem-
onstrated painlessly and with little or no detectable
sensation. These 100–250 µm diameter, 200 µm deep
openings are made repeatedly, quickly and painlessly
through sharp, inert particles microscissioning the tissues.
Accurate control of particle size, flux, carrier gas pressure,
area exposed to particles, and time of exposure is essential.
Microconduit diameter and depth can be controlled; no
foreign bodies were discernable after healing. In vivo
through-skin drug delivery, analyte access and signifi-
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